A large mitral paravalvular leak in a 63-year-old patient was closed by percutaneous placement of 2 Amplatzer Septal Occluder (AGA Medical Corporation, Plymouth, MN) devices. The patient had a residual paravalvular leak and subsequently developed infective endocarditis that was successfully treated by removal of all hardware and implantation of a new valve. Transcatheter treatment of paravalvular leaks may be useful in select patients who are poor candidates for open surgery; however, one must be aware of the potential complications. This report underscores the risk of device infection that may be increased if there is turbulence related to residual paravalvular leaks.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.athoracsur.2012.10.051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Ross procedure for recurrently failed aortic valve procedures.
Multimed Man Cardiothorac Surg
December 2024
B6-106 University Campus LHSC 339 Windermere Road London, ON N6A 5A5 Canada.
The Ross procedure provides young patients with unrepairable aortic valve disease with a living pulmonary autograft that confers significant survival benefit and improved quality of life. However, the procedure is complicated, and surgeons can be reluctant to offer it as a solution, especially in complex re-operative scenarios. We present a young patient with symptomatic, severe aortic insufficiency who had undergone two failed aortic valve procedures for congenital bicuspid aortic valve disease within the prior year.
View Article and Find Full Text PDFThree-Year Outcomes With a Supra-Annular, Self-Expanding Bioprosthesis and a Pericardial Wrap-The FORWARD PRO Study.
Catheter Cardiovasc Interv
December 2024
Center of Innovative Interventions in Cardiology, University Hospital Bonn, Bonn, Germany.
Background: The self-expanding, supra-annular Evolut valve is an established platform for Transcatheter Aortic Valve Implantation (TAVI). Evolut PRO introduced an outer sealing wrap to mitigate paravalvular leakage. We evaluated the 3-year clinical outcomes and valve performance of the Evolut PRO in standard clinical practice for severe aortic stenosis (AS) patients at intermediate or higher risk for surgery.
View Article and Find Full Text PDFThree-dimensional transesophageal echocardiographic guided transcatheter puncture of the interatrial septum for mitral valve-in-valve replacement for mitral bioprosthetic valve failure.
Acta Cardiol
December 2024
Department of Ultrasound, Wuhan Asia Heart Hospital Affiliated to Wuhan University of Science and Technology, Wuhan Clinical Medical Research Center of Cardiovascular Imaging, Wuhan, China.
Computational evaluation of interactive dynamics for a full transcatheter aortic valve device in a patient-specific aortic root.
Comput Biol Med
December 2024
Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Epinal Way, Loughborough, LE11 3TU, UK. Electronic address:
Transcatheter aortic valve implantation (TAVI) has become a key treatment for severe aortic stenosis, especially for patients unsuitable for surgery. Since its introduction in 2002, TAVI has advanced significantly due to improvements in imaging, operator skills, and device engineering. Despite these innovations, challenges in device sizing and positioning remain, complicating outcome predictions.
View Article and Find Full Text PDF1-Year Real-World Outcomes of TAVR With the Fifth-Generation Balloon-Expandable Valve in the United States.
JACC Cardiovasc Interv
November 2024
Division of Cardiology, Scripps Clinic, La Jolla, California, USA.
Background: Longer term outcomes of transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 Ultra RESILIA (S3UR) valve over its predecessors have not been reported in a national registry.
Objectives: The aim of this study was to compare the 1-year clinical and echocardiographic outcomes of the S3UR with those of the SAPIEN 3 (S3) and SAPIEN 3 Ultra (S3U) in the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry.
Methods: From September 2022 to March 2023, patients who underwent native TAVR with the S3UR or the S3 or S3U valve were propensity matched and compared.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!